Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Map kinase signaling pathways and hematologic malignancies.

Leonidas C Platanias1

  • 1Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago IL 60611, USA. l-platanias@northwestern.edu

Blood
|March 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.

Communications biology·2026
Same author

Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML.

Oncogenesis·2026
Same author

Development of a Direct-to-Biology Platform to Discover Potent MNK Inhibitors.

Journal of medicinal chemistry·2026
Same author

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

Blood advances·2026
Same author

Schlafen 5 is an intracellular immune checkpoint and controls IFN responses in pancreatic ductal adenocarcinoma.

JCI insight·2026
Same author

Mutant p53 promotes clonal hematopoiesis by generating a chronic inflammatory microenvironment.

The Journal of clinical investigation·2025

Mitogen-activated protein (Map) kinases are crucial in cell signaling and hematologic malignancies. Understanding Map kinase pathways offers new therapeutic targets for treating blood cancers.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Oncology

Background:

  • Mitogen-activated protein (Map) kinases are serine-threonine kinases involved in cellular signal transduction.
  • Three main Map kinase families exist: p38, extracellular signal-regulated kinase (Erk), and c-Jun NH2-terminal kinase (JNK).
  • Map kinases regulate critical cellular processes including gene transcription, cell death/survival, and cell-cycle progression.

Purpose of the Study:

  • To review the role of Map kinase pathways in the pathophysiology of hematologic malignancies.
  • To discuss the clinical implications of recent advances in Map kinase research for blood cancer treatment.

Main Methods:

  • Literature review of studies on Map kinase pathways in hematologic malignancies.
  • Analysis of the involvement of different Map kinase families (p38, Erk, JNK) in cancer development.

Related Experiment Videos

  • Discussion of therapeutic strategies targeting Map kinase pathways.

    • Main Results:

    • Map kinase pathways play a significant role in the development and progression of various hematologic malignancies.
    • Specific Map kinase isoforms can either promote or inhibit the growth of malignant hematopoietic cells.
    • Dysregulation of Map kinase signaling is implicated in malignant transformation and cell-cycle control in blood cancers.

    Conclusions:

    • Map kinase pathways are critical in hematologic malignancies, presenting viable molecular targets for novel therapies.
    • Targeting Map kinase signaling pathways holds promise for future therapeutic interventions in blood cancers.
    • Further research into Map kinase functions can lead to improved treatment strategies for hematologic cancers.